Prevalence of factor V 1691 G-A (Leiden) and prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients

Aydan Eroglu, Arzu Ulu, Ragip Çam, Cengiz Kurtman, Nejat Akar

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Aims: Cancer patients have an increased risk for thromboembolism (TE). Factor V 1691 G-A(Leiden) (FVL) and prothrombin (PT) G20210A mutation are common inherited risk factor for TE. The aim of the study is to evaluate the prevalence of FVL and PT G20210A polymorphism in cancer patients with and without TE as compared to patients with TE without malignancy and healthy control. Materials and methods: We have studied 43 cancer patients who developed TE during cancer treatment (group 1); 81 cancer patients without TE (group 2); 100 patients with TE without malignancy (group 3); 100 healthy control (group 4). FVL and PT G20210A polymorphisms were determined by the method of polymerase chain reaction-based DNA analysis. Results: The prevalence of FVL was significantly greater in cancer patients with TE (13 of 43, 30.2%) compared with other groups: 3.7% in group 2; 18% in group 3; 8% in group 4 (P < 0.0001). There was no significant difference in the prevalence of PT G20210A among the groups (P > 0.05). Conclusions: The study suggested that cancer patients with TE should be evaluated for FVL but PT G20210A was not contributing factor to the development of TE during cancer therapy.

Original languageEnglish (US)
Pages (from-to)31-34
Number of pages4
JournalJournal of Thrombosis and Thrombolysis
Volume23
Issue number1
DOIs
StatePublished - Feb 2007
Externally publishedYes

Fingerprint

Factor V
Thromboembolism
Prothrombin
Venous Thrombosis
Neoplasms
Polymerase Chain Reaction
Control Groups
Mutation

Keywords

  • Cancer
  • FVL
  • PT G20210A
  • Thromboembolism

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine

Cite this

Prevalence of factor V 1691 G-A (Leiden) and prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients. / Eroglu, Aydan; Ulu, Arzu; Çam, Ragip; Kurtman, Cengiz; Akar, Nejat.

In: Journal of Thrombosis and Thrombolysis, Vol. 23, No. 1, 02.2007, p. 31-34.

Research output: Contribution to journalArticle

Eroglu, Aydan ; Ulu, Arzu ; Çam, Ragip ; Kurtman, Cengiz ; Akar, Nejat. / Prevalence of factor V 1691 G-A (Leiden) and prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients. In: Journal of Thrombosis and Thrombolysis. 2007 ; Vol. 23, No. 1. pp. 31-34.
@article{5c9353ce4f5f467ea82f76a9ddb62d30,
title = "Prevalence of factor V 1691 G-A (Leiden) and prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients",
abstract = "Aims: Cancer patients have an increased risk for thromboembolism (TE). Factor V 1691 G-A(Leiden) (FVL) and prothrombin (PT) G20210A mutation are common inherited risk factor for TE. The aim of the study is to evaluate the prevalence of FVL and PT G20210A polymorphism in cancer patients with and without TE as compared to patients with TE without malignancy and healthy control. Materials and methods: We have studied 43 cancer patients who developed TE during cancer treatment (group 1); 81 cancer patients without TE (group 2); 100 patients with TE without malignancy (group 3); 100 healthy control (group 4). FVL and PT G20210A polymorphisms were determined by the method of polymerase chain reaction-based DNA analysis. Results: The prevalence of FVL was significantly greater in cancer patients with TE (13 of 43, 30.2{\%}) compared with other groups: 3.7{\%} in group 2; 18{\%} in group 3; 8{\%} in group 4 (P < 0.0001). There was no significant difference in the prevalence of PT G20210A among the groups (P > 0.05). Conclusions: The study suggested that cancer patients with TE should be evaluated for FVL but PT G20210A was not contributing factor to the development of TE during cancer therapy.",
keywords = "Cancer, FVL, PT G20210A, Thromboembolism",
author = "Aydan Eroglu and Arzu Ulu and Ragip {\cC}am and Cengiz Kurtman and Nejat Akar",
year = "2007",
month = "2",
doi = "10.1007/s11239-006-9001-z",
language = "English (US)",
volume = "23",
pages = "31--34",
journal = "Journal of Thrombosis and Thrombolysis",
issn = "0929-5305",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - Prevalence of factor V 1691 G-A (Leiden) and prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients

AU - Eroglu, Aydan

AU - Ulu, Arzu

AU - Çam, Ragip

AU - Kurtman, Cengiz

AU - Akar, Nejat

PY - 2007/2

Y1 - 2007/2

N2 - Aims: Cancer patients have an increased risk for thromboembolism (TE). Factor V 1691 G-A(Leiden) (FVL) and prothrombin (PT) G20210A mutation are common inherited risk factor for TE. The aim of the study is to evaluate the prevalence of FVL and PT G20210A polymorphism in cancer patients with and without TE as compared to patients with TE without malignancy and healthy control. Materials and methods: We have studied 43 cancer patients who developed TE during cancer treatment (group 1); 81 cancer patients without TE (group 2); 100 patients with TE without malignancy (group 3); 100 healthy control (group 4). FVL and PT G20210A polymorphisms were determined by the method of polymerase chain reaction-based DNA analysis. Results: The prevalence of FVL was significantly greater in cancer patients with TE (13 of 43, 30.2%) compared with other groups: 3.7% in group 2; 18% in group 3; 8% in group 4 (P < 0.0001). There was no significant difference in the prevalence of PT G20210A among the groups (P > 0.05). Conclusions: The study suggested that cancer patients with TE should be evaluated for FVL but PT G20210A was not contributing factor to the development of TE during cancer therapy.

AB - Aims: Cancer patients have an increased risk for thromboembolism (TE). Factor V 1691 G-A(Leiden) (FVL) and prothrombin (PT) G20210A mutation are common inherited risk factor for TE. The aim of the study is to evaluate the prevalence of FVL and PT G20210A polymorphism in cancer patients with and without TE as compared to patients with TE without malignancy and healthy control. Materials and methods: We have studied 43 cancer patients who developed TE during cancer treatment (group 1); 81 cancer patients without TE (group 2); 100 patients with TE without malignancy (group 3); 100 healthy control (group 4). FVL and PT G20210A polymorphisms were determined by the method of polymerase chain reaction-based DNA analysis. Results: The prevalence of FVL was significantly greater in cancer patients with TE (13 of 43, 30.2%) compared with other groups: 3.7% in group 2; 18% in group 3; 8% in group 4 (P < 0.0001). There was no significant difference in the prevalence of PT G20210A among the groups (P > 0.05). Conclusions: The study suggested that cancer patients with TE should be evaluated for FVL but PT G20210A was not contributing factor to the development of TE during cancer therapy.

KW - Cancer

KW - FVL

KW - PT G20210A

KW - Thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=33846989362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846989362&partnerID=8YFLogxK

U2 - 10.1007/s11239-006-9001-z

DO - 10.1007/s11239-006-9001-z

M3 - Article

C2 - 17106650

AN - SCOPUS:33846989362

VL - 23

SP - 31

EP - 34

JO - Journal of Thrombosis and Thrombolysis

JF - Journal of Thrombosis and Thrombolysis

SN - 0929-5305

IS - 1

ER -